by The Tamiflu (Oseltamivir Phosphate) is an oral antiviral drug used for treating and preventing influenza virus infection in adults and children. Tamiflu works by inhibiting the neuraminidase enzyme produced by influenza viruses, thus preventing the virus from spreading within the body. It provides early relief from flu symptoms and reduces the risk of complications arising from influenza.
The global Tamiflu (Oseltamivir Phosphate) Market is estimated to be valued at US$ 464.4 Mn in 2024 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing prevalence of influenza across the globe has been a major driver of the Tamiflu (Oseltamivir Phosphate) market. According to World Health Organization (WHO), there are 1 billion cases of influenza reported annually worldwide. Of these, 3 to 5 million cases are reported to be severe, leading to hospitalizations or deaths. The risk of influenza is high among children, elderly population and individuals with weak immunity. With limited vaccination coverage and nonexistence of universal vaccines for all influenza strains, antiviral drugs play a crucial role in the treatment and prevention of influenza. Threats from seasonal influenza as well as potential influenza pandemics have been spurring the uptake of Tamiflu globally.
SWOT Analysis
Strength: Tamiflu is the most commonly prescribed antiviral drug for influenza. It can be administered orally which offers convenience over intravenous antivirals.
Weakness: The window for effective treatment is limited, and Tamiflu should be administered within 48 hours of symptoms onset. It is less effective against influenza B virus strains compared to influenza A viruses.
Opportunity: The annual incidence of influenza provides ongoing market potential. Increasing awareness about stockpiling Tamiflu for pandemics can boost demand.
Threats: Intense competition from other established antivirals and generic versions poses pricing pressure. Potential resistance to Tamiflu strains can reduce its effectiveness over time.
Key Takeaways
The Global Tamiflu (Oseltamivir Phosphate) Market Size is expected to witness high growth over the forecast period of 2023 to 2030. The global Tamiflu (Oseltamivir Phosphate) Market is estimated to be valued at US$ 464.4 Mn in 2024 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030.
North America currently dominates the Tamiflu market and is expected to continue its lead position owing to growing influenza disease burden and well-established healthcare systems in countries like the United States and Canada. Asia Pacific is anticipated to be the fastest growing region due to increasing prescription volumes in major markets of China and India supported by improving access and rising health expenditures.
Key players operating in the Tamiflu (Oseltamivir Phosphate) market are Roche, Amneal Pharmaceuticals LLC, and Teva Pharmaceutical Industries Ltd. Roche holds a major share of the market currently while Amneal Pharmaceuticals and Teva Pharmaceuticals offer cost-effective generic versions. Allergan also launched a generic version in 2018 called Alvesco but holds a lower market share presently. With increasing focus on pandemic preparedness, global procurement of Tamiflu from these suppliers is expected to rise over the coming years.
*Note:
1.Source: Coherent Market Insights, Public sources, Desk research
2.We have leveraged AI tools to mine information and compile it
